type your search, and then press enter

News & Events

See what’s new in the field of hereditary eye diseases

Blog managed by the DBGen team, with updated therapies, news and events involving hereditary eye diseases. We invite you to take part in this forum.

Direct reprogramming of skin cells into photoreceptors in mice

27/05/20 - Research, Therapy, Cell Therapy,

The end result of many retinal dystrophies is photoreceptor cell death and the irreversible loss of vision. To prevent the progressive loss of retinal neurons, and to slow down or reverse the progression of the disease, gene therapies are currently under study to correct or replace the altered genes responsible for different retinopathies. Another therapeutic strategy that is under intensive...

read more

Advances in gene therapy for retinitis pigmentosa due to RPGR gene mutation

In the first months of 2020, positive results in gene therapy of X-linked retinitis pigmentosa (XLRP) have been reported. XLRP is an inherited genetic disorder that causes progressive vision loss, mainly in men. It begins in childhood with night blindness, progresses with the gradual reduction of the visual field and visual acuity, and leads to blindness in the fourth decade...

read more

DBGen and the UB-CIBERER U-718 group present their current research in genetic diagnosis and animal models of inherited retinal dystrophies in ARVO 2019

Dr. Gemma Marfany (co-founder and scientific board member of DBGen) presented an oral communication in ARVO 2019 (held in Vancouver, 2-6 May) to show the most prominent results of the research that his group at the UB-CIBERER (U-718) and DBGEN are currently undertaking to study inherited retinal dystrophies. This work is focused on improved genetic diagnosis and the generation of...

read more

Small chaperones to treat retinitis pigmentosa

Rhodopsin is the main photopigment in rods. Many mutations in the rhodopsin gene translate into a misfolded nonfunctional protein that is toxic, thus causing photoreceptor death and premature retinitis pigmentosa. Many research groups are looking for therapeutic approaches to treat this type of untreatable retinal dystrophy, for instance by CRISPR/Cas9 gene editing. Nonetheless, a group has just reported (Chen et...

read more

Latest reports on retinal dystrophy gene therapy clinical trials

Recently, a worldwide congress on vision research, ARVO 2018, was held on the 29th April-2nd May in Honolulu. Several sessions were dedicated to present the latest reports on retinal dystrophy gene therapy clinical trials. Gene therapy is a type of precision medicine that aims to treat the genetic defect behind a particular disorder, thus gene therapy is developed for patients...

read more
Copyright © 2020. All Rights Reserved -